News Jounce elopes with Concentra, leaving Redx at the altar A $425 million proposed marriage between Redx Pharma of the UK and Jounce Ther
News Concentra gatecrashes Jounce and Redx’ merger party Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
R&D The Alderley Park Discovery Podcast: The journey to accessin... Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract investors.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends